Bench to bedside radiosensitizer development strategy for newly diagnosed glioblastoma
{{output}}
Glioblastoma is the most common primary brain malignancy and carries with it a poor prognosis. New agents are urgently needed, however nearly all Phase III trials of GBM patients of the past 25 years have failed to demonstrate improvement in outcomes. In 2019,... ...
